Asahi Songwon Colors Limited H1FY27 profit rises 623% year on year

Asahi Songwon Colors Limited reported consolidated H1FY27 net profit of Rs 33.92 crore for the half year ended September 30, 2026, up 622.95% year on year, as revenue rose 44.13% to Rs 390.27 crore and EBITDA margin increased to 15.15% from 8.45%.

What drove ASCL's H1FY27 profit increase?

ASCL's H1FY27 profit increase was driven by higher revenue and a much faster rise in EBITDA during the half year ended September 30, 2026. Consolidated revenue reached Rs 390.27 crore, with year-on-year growth of 44.13%, while earnings before interest, tax, depreciation and amortisation (EBITDA) rose 157.29% to Rs 59.56 crore. Net profit of Rs 33.92 crore increased 622.95% from the corresponding H1FY26 period.

The profit growth was accompanied by a 6.70-percentage-point expansion in EBITDA margin, to 15.15% in H1FY27 from 8.45% in H1FY26. Management attributed the margin outcome to its supply chain during raw-material supply and price disruptions, as well as engineering efficiencies and ground-level cost reductions implemented over several quarters. The chief executive said a good part of these cost gains is structural and embedded in plant operations.

ASCL's Q2FY27 performance formed part of the first-half result, with consolidated revenue of Rs 201.36 crore, EBITDA of Rs 26.96 crore and net profit of Rs 14.89 crore. These figures represented year-on-year increases of 66.55%, 141.92% and 610.16%, respectively. The company described the quarter as particularly strong for its phthalocyanine pigment business.

The release reports H1FY27 revenue of Rs 390.27 crore and Q2FY27 revenue of Rs 201.36 crore, but does not separately disclose first-quarter financial results in this announcement. It therefore does not provide a direct explanation for the difference between the half-year EBITDA margin of 15.15% and the Q2 margin of 13.25%.

How did ASCL's margins change in Q2FY27 and H1FY27?

ASCL expanded EBITDA margin in both reported periods, with Q2FY27 margin reaching 13.25% from 9.09% in Q2FY26 and H1FY27 margin reaching 15.15% from 8.45% in H1FY26. The Q2 increase was 4.16 percentage points, while the first-half increase was 6.70 percentage points, meaning EBITDA growth exceeded revenue growth in each year-on-year comparison.

The H1FY27 EBITDA margin of 15.15% was 1.90 percentage points above Q2FY27's 13.25%. The release does not give standalone first-quarter figures or explain that gap directly. It does cite sustained cost work and supply-chain execution as factors behind the margin improvement recorded during the September 2026 quarter and first half.

Management said ASCL can sustain an EBITDA margin of 13% to 15% over the longer term. This is management's stated expectation rather than financial guidance with a specified period. The reported H1FY27 margin of 15.15% was slightly above that range, whereas Q2FY27's 13.25% was within it.

Which ASCL segments generated revenue in H1FY27?

ASCL's phthalocyanine segment generated the largest reported H1FY27 revenue, at Rs 270.82 crore, followed by active pharmaceutical ingredients (API) at Rs 72.10 crore and AZO at Rs 47.35 crore. These three segment figures total the company's reported consolidated H1FY27 revenue of Rs 390.27 crore for the half year ended September 30, 2026.

Phthalocyanine also led Q2FY27 revenue at Rs 134.90 crore, while API contributed Rs 37.64 crore and AZO contributed Rs 28.82 crore. The Q2 segment total was Rs 201.36 crore. Management specifically identified the phthalocyanine pigment business as very strong in the quarter, linking it to revenue growth and margin expansion versus Q2FY26.

ASCL said its AZO operation faced a challenging Q2FY27 and performed below management expectations, although sales recovered to earlier levels after a difficult first quarter. Management said AZO volumes had grown well and the business remained EBITDA-positive and cash-positive, but pricing conditions were still tough. Its stated focus is to win larger customers while improving product quality and cost.

What does ASCL expect for H2FY27?

ASCL expects Q3FY27 to be significantly better than Q3 of the previous year, although management said demand normally softens in the quarter as customers manage inventories more tightly toward the calendar year-end. This outlook follows Q2FY27 revenue of Rs 201.36 crore and EBITDA of Rs 26.96 crore, rather than a disclosed numerical forecast for the third quarter.

For AZO, management expects H2FY27 to be better than H1FY27 after the segment recorded Rs 47.35 crore of revenue in the first half. The managing director said industry changes expected globally had not occurred as anticipated, while pricing remained difficult. Management nevertheless cited sales recovery, volume growth and efforts to improve quality and costs as the basis for its second-half expectation.

For API, ASCL said volumes have grown at almost 18% a year over the past three years, but price pressure has held back performance. The API segment generated Rs 72.10 crore in H1FY27 and Rs 37.64 crore in Q2FY27. Management expects API performance to improve in the second half as price pressure eases, an outcome that remains dependent on the pricing environment described in the release.

ASCL also reported continued deleveraging, saying it reduced gross borrowings by about Rs 49 crore during H1FY27 through strong cash generation across its businesses. Management said the balance sheet was considerably stronger and that the group was evaluating appropriate opportunities for its next growth phase as debt declines and profitability improves. The announcement did not disclose closing gross borrowings, a debt-to-equity ratio, or a timetable for any growth investment.

Conclusion

ASCL's H1FY27 results combined higher scale with higher profitability: revenue rose 44.13% to Rs 390.27 crore, EBITDA rose 157.29% to Rs 59.56 crore, and net profit rose 622.95% to Rs 33.92 crore. The increase in EBITDA margin to 15.15% from 8.45% indicates that earnings grew faster than sales, with management attributing the outcome to supply-chain execution and structural operating-cost reductions.

The next reported test is Q3FY27, when management expects seasonal inventory-related demand softness but says results should be significantly better than Q3 of the prior year. Investors will also watch whether AZO improves after Rs 47.35 crore of H1FY27 revenue, whether API pricing pressure eases, and whether deleveraging continues after the approximately Rs 49 crore reduction in gross borrowings during the first half.